Back to search

Article

Population Pharmacokinetics of Brexpiprazole in Japanese Healthy Subjects and Patients with Schizophrenia

2024-10-30

Abstract excerpt

<title>Abstract</title> <p>Brexpiprazole, widely approved for the treatment of schizophrenia, is an atypical antipsychotic that modulates serotonin–dopamine activity. To better understand the pharmacokinetics (PK) of brexpiprazole in Japanese patients, a population PK model was constructed and used to estimate steady state PK profiles and parameters as well as dopamine D<sub>2</sub>/D<sub>3</sub> receptor occupan...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
0d0301bd-3ad0-55cd-a05f-0d327c7ffcbc
DOI
10.21203/rs.3.rs-5352712/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Population Pharmacokinetics of Brexpiprazole in Japanese Healthy Subjects and Patients with SchizophreniaDOI 10.21203/rs.3.rs-5352712/v1
Population pharmacokinetics of aripiprazole in healthy Korean subjects.Semantic proximity
Population pharmacokinetic-pharmacodynamic (PopPK/PD) modeling of risperidone and its active metabolite in Chinese schizophrenia patients.Semantic proximity
Brexpiprazole Pharmacokinetics in CYP2D6 Poor Metabolizers: Using Physiologically Based Pharmacokinetic Modeling to Optimize Time to Effective Concentrations.Semantic proximity
Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.Semantic proximity
Effects of CYP1A2 Polymorphisms on the Steady-State Plasma Concentrations of Aripiprazole and Its Active Metabolite, Dehydroaripiprazole, in Japanese Patients with SchizophreniaSemantic proximity
Influences of CYP2D6*10 polymorphisms on the pharmacokinetics of iloperidone and its metabolites in Chinese patients with schizophrenia: a population pharmacokinetic analysis.Semantic proximity
Simple pharmacokinetic models accounting for drug monitoring results of atomoxetine and its 4-hydroxylated metabolites in Japanese pediatric patients genotyped for cytochrome P450 2D6.Semantic proximity
Physiologically based pharmacokinetic modeling to predict exposures in healthy Japanese subjects with different CYP2C19 phenotypes: Esomeprazole case study .Semantic proximity
Population Pharmacokinetics Study of Morinidazole in Patients with Moderate Hepatic ImpairmentSemantic proximity
Investigating the Effectiveness of Brexpiprazole in Schizophrenic Patients with Concurrent Alcohol and Substance Use Disorder: A Prospective, Multicentric, Real-World StudySemantic proximity
“The Efficacy and Safety of Aripiprazole and Paliperidone 1 and 3-Month Long-Acting Preparations During The Maintenance of Schizophrenia in Clinical Practice”Semantic proximity
The impact of CYP3A5*3 on oral quetiapine: A population pharmacokinetic model in Chinese bipolar disorder patients.Semantic proximity
Select a neighboring publication to make it the new centre.